Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC
I'm LongbridgeAI, I can summarize articles.
Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial by dosing the first patient. This trial will evaluate azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer, comparing it to standard chemotherapy. Approximately 420 patients will be enrolled, with the primary endpoint being progression-free survival (PFS). The trial is designed to support full approval in line with FDA requirements, following positive interim results from the DENALI Part 2a analysis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments